

PART II

A PARTICULARS OF SHAREHOLDING						
1	Public shareholding - Number of shares - Percentage of shareholding	3059150 95.6	3294950 38.74	3059150 95.6	3059150 95.6	3059150 95.6
2	Promoter and Promoter Group Shareholding ** a) Pledged / Encumbered - Number of shares Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	0 0 0 0 140850 100 4.4	0 0 0 0 5209916 100 61.26	0 0 0 0 140850 100 4.4	0 0 0 0 140850 100 4.4	0 0 0 0 140850 100 4.4

B INVESTOR COMPLAINTS		
Particulars		
		31.03.2012
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

Audited Statement of Assets and Liabilities as at March 31, 2012						
			Standalone		Consolidated	
			Year Ended As At		Year Ended As At	
			31.03.2012	31.03.2011	31.03.2012	
A	EQUITY AND LIABILITIES					
1	Shareholders' funds					
	(a) Share capital		85,048,660	32,000,000	85,048,660	
	(b) Reserves and surplus		69,217,793	3,127,363	95,318,279	
	(c) Money received against share warrants		----	----	----	
	Sub-total - Shareholders' funds		154,266,453	35,127,363	180,366,939	
2	Share application money pending allotment					
			----	----	----	
3	Minority interest					
			----	----	252,306	
4	Non-current liabilities					
	(a) Long-term borrowings		87,501,255	615,000	128,967,142	
	(b) Deferred tax liabilities (net)		----	----	----	
	(c) Other long-term liabilities		----	----	----	
	(d) Long-term provisions		----	----	----	
	Sub-total - Non-current liabilities		87,501,255	615,000	128,967,142	
5	Current liabilities					
	(a) Short-term borrowings		76,191,848	----	130,446,423	
	(b) Trade Payables		64,839,220	168,985	130,625,829	
	(c) Other current liabilities		4,461,168	43,494	29,502,717	
	(d) Short-term provisions		----	----	4,961,418	
	Sub-total - current liabilities		145,492,236	212,479	295,536,387	
	TOTAL - EQUITY AND LIABILITIES		387,259,944	35,954,842	605,122,775	
B	ASSETS					
1	Non-current assets					
	(a) Fixed assets		93,025,613	----	333,131,841	
	(b) Goodwill on consolidation *		----	----	----	
	(c) Non-current investments		106,931,913	----	7,131,913	
	(d) Deferred tax assets (net)		11,344,327	----	11,344,327	
	(e) Long-term loans and advances		34,422,377	34,408,652	35,704,647	
	(f) Other non-current assets		252,194	56,000	287,194	
	Sub-total - Non-current Assets		245,976,424	34,464,652	387,599,921	
2	Current assets					
	(a) Current investments		----	----	----	
	(b) Inventories		47,691,199	----	68,082,851	
	(c) Trade receivables		65,581,694	373,843	112,841,654	
	(d) Cash and cash equivalents		(3,061,007)	150,630	(6,557,041)	
	(e) Short-term loans and advances		31,071,634	965,717	43,155,390	
	(f) Other current assets		----	----	----	
	Sub-total - Current Assets		141,283,520	1,490,190	217,522,854	
	TOTAL - ASSETS		387,259,944	35,954,842	605,122,775	

Notes:	
1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 6, 2012
2	The Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprise the results of Parnax Lab Limited and One Subsidiary Company
3	Pursuant to approval of Registrar of Companies, Mumbai, the name of the Company is changed to Parnax Lab Ltd w e f April 2, 2012
4	Pursuant to merger approval received from Hon'ble High Court of Bombay w.e.f. January 2, 2012, the annual accounts for full financial year 2011-12 have been prepared on the basis of Merged Entity, owing to which the figures of the last quarter are not the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.
5	Since there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.
6	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
7	EPS for quarter ended is on non annualised basis.
8	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations

Date:06.07.2012
Place: Mumbai

For Parnax Lab Limited



Whole Time Director